Oral News and Research

RSS

UPM researchers assess potential risk for human health associated with metals in urban gardens

Researchers from UPM the assess the human health risk of exposure to metals in urban gardens by assessing their oral bioaccessibility.

12 Nov 2015

Ovarian cancer patients with a history of oral contraceptive use have better outcomes

Patients who develop ovarian cancer appear to have better outcomes if they have a history of oral contraceptive use, according to a study by Mayo Clinic researchers published in the current issue of the journal BMC Cancer.

12 Nov 2015

Research shows prevalence of Mycoplasma genitalium in up to 1% of general population in the UK

A new study strengthens growing evidence that Mycoplasma genitalium (MG) is a sexually transmitted infection (STI). The findings are recently published in the International Journal of Epidemiology.

12 Nov 2015

MedTechSouthEast competition displays advanced medical technologies for Parkinson’s patients

Laser-emitting shoes and a Meccano-style walking aid kit are just two of the inventions being developed by companies in London and the south east that could help people stay independent for longer as they get older or develop debilitating illnesses, according to Design Council and MedCity, the Mayor of London’s life sciences promotional organisation.

12 Nov 2015

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.

11 Nov 2015

Screening for asymptomatic atrial fibrillation could reduce risk of stroke, premature death

Screening for asymptomatic atrial fibrillation (AF) in people aged 65 and over and treating it with anticoagulant medications could greatly reduce the risk of stroke and premature death, say cardiologists in today's Journal of the American Medical Association.

10 Nov 2015

New Cleveland Clinic study shows bariatric surgery is safe option for managing type 2 diabetes in overweight or mildly obese patients

Weight-loss surgery, long considered a treatment largely reserved for people with severe obesity, may also be a good and safe option for the treatment of uncontrolled type 2 diabetes in those who are overweight or have mild to moderate obesity, according to researchers from Cleveland Clinic in Ohio.

10 Nov 2015

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

First comprehensive genomic and biologic study of top skin disease-causing microbes

An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.

9 Nov 2015

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Inhaled anesthetics are fairly common all over the world for minor and extensive surgical procedures in patients of all age groups. In the olden days when anesthesia was first developed, ether was the first inhaled anesthetic. That has been replaced, with the more recent discoveries of sevoflurane, isoflurane, and desflurane.

9 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

Better visualization in complex reconstructive surgery with ZEISS Opmi Pentero 800 surgical microscope

The capabilities of the OPMI® PENTERO® 800 surgical microscopes from ZEISS for reconstructive surgery have been enhanced by the introduction of the INFRARED 800 module.

From ZEISS Microscopy GmbH 6 Nov 2015

MPP announces expansion of mandate to hepatitis C and TB medicines

The Medicines Patent Pool, the world's only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines. The UNITAID Executive Board, meeting November 4-5 in Geneva, approved the MPP's proposals to improve access to both life-saving direct acting antivirals (DAAs) to treat hepatitis C and new and re-purposed medicines for tuberculosis.

6 Nov 2015

Mucus plays important role in defending invaders

By licking a wound it heals faster - this is not simply popular belief, but scientifically proven. Our saliva consists of water and mucus, among other things, and the mucus plays an important role. It stimulates white blood cells to build a good defence against invaders, according to a group of researchers at Lund University in Sweden together with colleagues from Copenhagen and Odense in Denmark.

6 Nov 2015

Weight-loss surgery may be safe for managing type 2 diabetes in patients with mild obesity

6 Nov 2015

Two genetic variants interact to alter the brain responses to high-calorie foods

For the first time, researchers have identified two genetic variants that interact to alter the brain responses to high-calorie foods, a tie that could aid in the development of targeted treatments for obesity and overweight. Researchers at Imperial College London led by Tony Goldstone, MD, PhD, of Consultant Endocrinologist, found that two gene variants - FTO and DRD2 - influenced activity in the brain reward system when looking at pictures of high-calorie foods.

6 Nov 2015

Sleep loss reduces insulin sensitivity, increases diabetes risk

A new study by the University of Colorado shows that the longer people are awake during the time their biological clock is telling them to sleep the worse their sensitivity to insulin, which is a precursor to diabetes.

6 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Oral News and Research

UPM researchers assess potential risk for human health associated with metals in urban gardens

Ovarian cancer patients with a history of oral contraceptive use have better outcomes

Research shows prevalence of Mycoplasma genitalium in up to 1% of general population in the UK

MedTechSouthEast competition displays advanced medical technologies for Parkinson’s patients

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

Screening for asymptomatic atrial fibrillation could reduce risk of stroke, premature death

New Cleveland Clinic study shows bariatric surgery is safe option for managing type 2 diabetes in overweight or mildly obese patients

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

First comprehensive genomic and biologic study of top skin disease-causing microbes

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Better visualization in complex reconstructive surgery with ZEISS Opmi Pentero 800 surgical microscope

MPP announces expansion of mandate to hepatitis C and TB medicines

Mucus plays important role in defending invaders

Weight-loss surgery may be safe for managing type 2 diabetes in patients with mild obesity

Two genetic variants interact to alter the brain responses to high-calorie foods

Sleep loss reduces insulin sensitivity, increases diabetes risk

New tool could help identify patients most likely to benefit from chemoprevention

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News